PET and MR-Compatible Bioreactor for Cross-Platform Biomarker Development

用于跨平台生物标志物开发的 PET 和 MR 兼容生物反应器

基本信息

项目摘要

DESCRIPTION (provided by applicant): The goal of this research is to optimize a 5mm MR-compatible PET 3D cell/tissue culture bioreactor and test it by using a combination of hyperpolarized (HP) 13C MR and PET probes. Three-dimensional (3D) cell and tissue culture bioreactors provide a novel platform to investigate, in a very controlled and cost effective environment, cell and tissue metabolism and function as well as response to therapy. Combining HP 13C labeled MR probes with MR-compatible 3D tissue culture bioreactors has allowed the monitoring of metabolic fluxes with high temporal resolution (seconds) without background signals from the culture media. The addition of positron emission tomography (PET) imaging with an array of labeled tracers provides yet another dimension to understanding metabolic function, protein interaction, signaling pathways and drug pharmacokinetics/pharmacodynamics (PK/PD), in the bioreactor system. Both hyperpolarized 13C MR and PET have advantages and disadvantages, yet there is great interest in investigating their complimentary roles in the setting of providing companion imaging biomarkers for assessing new therapies. To accomplish this we will optimize a 5mm MR-compatible PET Bioreactor (aim 1) and use this platform to investigate the synergistic role of PET and HP MR (aim 2). The test studies aim to demonstrate the breadth of application of this cross- platform bioreactor system, spanning both multinuclear PET and MR. Adapting existing micro-engineered MR compatible 3D culture bioreactor designs for PET imaging studies represents a novel direction that will have a major impact on screening and evaluation of new radiotracers and therapeutics, and in identifying the synergistic role of HP MR and PET for future clinical applications. The proposed studies will also provide new information concerning the synergistic role of MR and PET probes. This optimized 5 mm bioreactor can be further micro-engineered to allow the study of smaller amounts of primary human cells and tissues, including biopsy samples, ultimately influencing patient management.
描述(由申请人提供):本研究的目标是优化5 mm MR兼容PET 3D细胞/组织培养生物反应器,并通过使用超极化(HP)13 C MR和PET探头的组合对其进行测试。三维(3D)细胞和组织培养生物反应器提供了一个新的平台,在一个非常受控和成本效益的环境,细胞和组织的代谢和功能,以及对治疗的反应。将HP 13 C标记的MR探针与MR兼容的3D组织培养生物反应器组合,允许在没有来自培养基的背景信号的情况下以高时间分辨率(秒)监测代谢通量。添加具有标记示踪剂阵列的正电子发射断层扫描(PET)成像为理解生物反应器系统中的代谢功能、蛋白质相互作用、信号传导途径和药物药代动力学/药效学(PK/PD)提供了又一个维度。超极化13 C MR和PET都有优点和缺点,但人们对研究它们在为评估新疗法提供伴随成像生物标志物方面的互补作用非常感兴趣。为了实现这一目标,我们将优化5 mm MR兼容PET生物反应器(目的1),并使用该平台研究PET和HP MR的协同作用(目的2)。测试研究旨在证明这种跨平台生物反应器系统的应用广度,跨越多核PET和MR。将现有的微工程MR兼容3D培养生物反应器设计用于PET成像研究代表了一个新的方向,其将对新的放射性示踪剂和治疗剂的筛选和评估产生重大影响,以及在确定HP MR和PET的协同作用以用于未来的临床应用中。拟议的研究还将提供有关MR和PET探针协同作用的新信息。这种优化的5 mm生物反应器可以进一步进行微工程设计,以允许研究少量的原代人类细胞和组织,包括活检样本,最终影响患者管理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Kurhanewicz其他文献

John Kurhanewicz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Kurhanewicz', 18)}}的其他基金

High Field MRI For Optimized Translational 1H Multiparametric and Multinuclear Imaging Research
用于优化平移 1H 多参数和多核成像研究的高场 MRI
  • 批准号:
    10175910
  • 财政年份:
    2021
  • 资助金额:
    $ 15.32万
  • 项目类别:
Preclinical imaging characterization and resource development of PDX SCNC prostate cancer murine models
PDX SCNC 前列腺癌小鼠模型的临床前成像特征和资源开发
  • 批准号:
    10378320
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
  • 批准号:
    10669081
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
  • 批准号:
    10057724
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
  • 批准号:
    10470345
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Characterization of PDX SCNC prostate cancer metastatic murine models and development of associated research resources
PDX SCNC 前列腺癌转移小鼠模型的表征和相关研究资源的开发
  • 批准号:
    10533469
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
  • 批准号:
    10256057
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
  • 批准号:
    10737795
  • 财政年份:
    2020
  • 资助金额:
    $ 15.32万
  • 项目类别:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
肾细胞癌患者来源模型的代谢成像比较
  • 批准号:
    9753176
  • 财政年份:
    2017
  • 资助金额:
    $ 15.32万
  • 项目类别:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
肾细胞癌患者来源模型的代谢成像比较
  • 批准号:
    10227078
  • 财政年份:
    2017
  • 资助金额:
    $ 15.32万
  • 项目类别:

相似海外基金

Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
  • 批准号:
    10930196
  • 财政年份:
    2023
  • 资助金额:
    $ 15.32万
  • 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
  • 批准号:
    10735807
  • 财政年份:
    2023
  • 资助金额:
    $ 15.32万
  • 项目类别:
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
  • 批准号:
    10418461
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
  • 批准号:
    RGPIN-2019-04999
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
    Discovery Grants Program - Individual
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10570208
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10688086
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10355174
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
  • 批准号:
    10431620
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
  • 批准号:
    2744296
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
    Studentship
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10525097
  • 财政年份:
    2022
  • 资助金额:
    $ 15.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了